Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Threshold Pharmaceuticals Announces Preliminary Data From Phase 1/2 Study of TH-302 in Combination With Bevacizumab in Patients With Recurrent Glioblastoma
Threshold Pharmaceuticals Announces Preliminary Data From Phase 1/2 Study of TH-302 in Combination With Bevacizumab in Patients With Recurrent Glioblastoma
Threshold Pharmaceuticals Announces Preliminary Data From Phase 1/2 Study of TH-302 in Combination With Bevacizumab in Patients With Recurrent Glioblastoma
Submitted by
admin
on September 30, 2012 - 10:33am
Source:
Yahoo/MarketWire
News Tags:
glioblastoma
bevacizumab
TH-302
Threshold Pharmaceuticals
Headline:
Threshold Pharmaceuticals Announces Preliminary Data From Phase 1/2 Study of TH-302 in Combination With Bevacizumab in Patients With Recurrent Glioblastoma
Do Not Allow Advertisers to Use My Personal information
